KR20180088455A - 사이토카인 생산의 조절 - Google Patents

사이토카인 생산의 조절 Download PDF

Info

Publication number
KR20180088455A
KR20180088455A KR1020187019002A KR20187019002A KR20180088455A KR 20180088455 A KR20180088455 A KR 20180088455A KR 1020187019002 A KR1020187019002 A KR 1020187019002A KR 20187019002 A KR20187019002 A KR 20187019002A KR 20180088455 A KR20180088455 A KR 20180088455A
Authority
KR
South Korea
Prior art keywords
c6orf106
ser
gly
gln
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187019002A
Other languages
English (en)
Korean (ko)
Inventor
카메론 스튜어트
레베카 앰브로스
앤드류 빈
Original Assignee
커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905035A external-priority patent/AU2015905035A0/en
Application filed by 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 filed Critical 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션
Publication of KR20180088455A publication Critical patent/KR20180088455A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
KR1020187019002A 2015-12-04 2016-12-02 사이토카인 생산의 조절 Ceased KR20180088455A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905035A AU2015905035A0 (en) 2015-12-04 Regulation of cytokine production
AU2015905035 2015-12-04
PCT/AU2016/051192 WO2017091866A1 (en) 2015-12-04 2016-12-02 Regulation of cytokine production

Publications (1)

Publication Number Publication Date
KR20180088455A true KR20180088455A (ko) 2018-08-03

Family

ID=58796001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019002A Ceased KR20180088455A (ko) 2015-12-04 2016-12-02 사이토카인 생산의 조절

Country Status (8)

Country Link
US (1) US20180362625A1 (https=)
EP (1) EP3383408A4 (https=)
JP (3) JP2019503998A (https=)
KR (1) KR20180088455A (https=)
CN (1) CN108601794A (https=)
AU (2) AU2016363114B2 (https=)
CA (1) CA3007287A1 (https=)
WO (1) WO2017091866A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
CN107964564B (zh) * 2017-12-28 2020-09-11 中南大学湘雅医院 胶质瘤诊断标志物circ6:34606555|34606904及应用
KR102805517B1 (ko) * 2022-12-22 2025-05-12 주식회사 셀렉소바이오 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법
CN120189429B (zh) * 2025-05-09 2026-02-27 中国科学院生物物理研究所 靶向C6orf223蛋白的抑制剂在制备治疗肿瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313313A (zh) * 2000-03-10 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人cdc4类似蛋白12和编码这种多肽的多核苷酸
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
KR101629963B1 (ko) * 2008-07-21 2016-06-14 경희대학교 산학협력단 염증성 질환 진단용 ｃＤＮＡ 마이크로어레이 칩
CN101773668B (zh) * 2009-01-09 2012-09-12 中国科学院上海生命科学研究院 一种抗病毒相关蛋白及其用途

Also Published As

Publication number Publication date
CN108601794A (zh) 2018-09-28
US20180362625A1 (en) 2018-12-20
EP3383408A4 (en) 2019-06-26
AU2016363114A1 (en) 2018-07-05
WO2017091866A1 (en) 2017-06-08
EP3383408A1 (en) 2018-10-10
AU2016363114B2 (en) 2023-04-20
AU2023204701A1 (en) 2023-09-28
CA3007287A1 (en) 2017-06-08
JP2022028689A (ja) 2022-02-16
JP2024041751A (ja) 2024-03-27
JP2019503998A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
Ma et al. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus
AU2023204701A1 (en) Regulation of cytokine production
JP7776176B2 (ja) 環状ｒｎａを調製するための構築物及び方法
US11118166B2 (en) Production of viruses in avian eggs
US20200157237A1 (en) Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
KR20200051808A (ko) 진핵 세포에서 유전자 발현을 침묵시키기 위한 비-암호화 rna 분자의 특이성의 변형
BR112019025358A2 (pt) ovo aviário transgênico, ave transgênica, ovo ou progênie aviária, método para detectar um ovo aviário macho, método para produzir um ovo aviário, método para replicar um vírus, vírus produzidos pelo uso de ovo aviário, método para produzir uma composição de vacina, composição da vacina produzida pelo uso do método e método para produzir um ovo aviário transgênico ou uma ave produzida pelo ovo
JP2011529708A (ja) 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
Li et al. Rabies virus phosphoprotein interacts with ribosomal protein L9 and affects rabies virus replication
WO2015084264A1 (en) Polypeptides, nucleic acids and uses thereof
Linder et al. Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner
CN108603188A (zh) 在细胞培养物中产生病毒
CN119563038A (zh) 用于调节免疫应答的组合物和方法
Du et al. IFITM3 inhibits severe fever with thrombocytopenia syndrome virus entry and interacts with viral Gc protein
Kuwabara et al. Recognition of Engineered tRNAs with an Extended 3 ‘End by Exportin-t (Xpo-t) and Transport of tRNA-Attached Ribozymes to the Cytoplasm in Somatic Cells
Wei et al. Design of antibody structure-guided epitope vaccines in silico to induce potent immune responses against emerging viruses
JP6653120B2 (ja) Ｉｋａｒｏｓ阻害に基づく抗炎症薬
US20230277618A1 (en) Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
Duan et al. The G allele of SNP rs3922 reduces the binding affinity between IGF2BP3 and CXCR5 correlating with a lower antibody production
EP4467563A1 (en) Ldlr derived polypeptides for anti-viral uses
Khalfi et al. Unraveling human, rodent and snake Kolmioviridae replication to anticipate cross-species transmission
CN102071196A (zh) 抑制犬p53基因表达的siRNA和p53基因沉默的犬细胞模型
EP4688822A1 (en) Ldlr derived polypeptides for anti-viral uses
WO2025216732A1 (en) Methods and compositions relating to ecdna biogenesis
JP6874996B2 (ja) 人工ｒｎａ制限酵素

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211201

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240821

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250225

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D